论文部分内容阅读
为了解慢性非甲非乙型肝炎病人丙型肝炎病毒血症水平及干扰素(IFN)对丙型肝炎的抗病毒效果,本文检测了30名群体获得性并经活检证实的慢性非甲非乙型肝炎病人血清中抗丙型肝炎病毒C-100蛋白的抗体,并对其中20名抗体水平增高者进行为期6个月的跟踪调查,在这期间对其中7名患者进行重组α-IFN的治疗。以丙型肝炎病毒基因组高度保守的5’非编码区合成两引物进行定量多聚酶链反应(PCR),检测20名抗C-100蛋白抗体阳性患者中19名及10名抗体阴性者中5名的丙型肝炎病毒RNA。治疗前患者病毒血症水平为2×10~3～2×10~(3)/ml基因组。6个月IFN
To understand the level of hepatitis C viremia in patients with chronic non-A, non-B hepatitis and the antiviral effect of interferon (IFN) on hepatitis C, 30 non-A non-B Hepatitis C patients were tested for antibodies against hepatitis C virus C-100 protein and followed up for a period of 6 months for 20 of them, during which time 7 patients were treated with recombinant α-IFN . Two primers were synthesized by polymerase chain reaction (PCR) with the 5 ’non-coding region highly conserved in the genome of hepatitis C virus. Twenty-five out of 20 anti-C-100 antibody-positive patients and 5 out of 10 antibody negative patients Hepatitis C virus RNA. Before treatment, patients with viremia levels of 2 × 10 ~ 3 ~ 2 × 10 ~ (3) / ml genome. 6 months IFN